Cost-effectiveness of tezepelumab in Canada for severe asthma

References

• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2021.
   Google Scholar
• FitzGerald JM, Lemiere C, Lougheed MD, et al. Recognition and management of severe asthma: a Canadian thoracic society position statement. Can J Respir Crit Care Sleep Med. 2017;1(4):199–221. doi: 10.1080/24745332.2017.1395250.
   Web of Science ®Google Scholar
• Statistics Canada. Table 13-10-0096-01 Health characteristics, annual estimates 2021 October 2021]. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1310009601.
   Google Scholar
• Denton EP, Tran DB, Canonica TN, et al. Cluster analysis of inflammatory biomarker expression in -the international severe asthma registry. J Allergy Clin Immunol Pract. 2021; (7):2680–2688 e7. doi: 10.1016/j.jaip.2021.02.059.
   PubMed Web of Science ®Google Scholar
• Ding B, Chen S, Agrawal A, et al. Distribution of biomarkers in severe asthma and severe uncontrolled asthma. Eur Respiratory Soc. 2021;58:OA4214. doi: 10.1183/13993003.congress-2021.OA4214.
   Web of Science ®Google Scholar
• Kupczyk M, Dahlén B, Sterk P, et al. Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy. 2014;69(9):1198–1204. doi: 10.1111/all.12445.
   PubMed Web of Science ®Google Scholar
• Xu X, O”Quinn S, Hirsch I, et al. Impact of asthma control status on lung function and patient well-being assessments in patients with severe asthma. A35. SEVERE ASTHMA: American Thoracic Society. 2017;195:A1370–A1370.
   Google Scholar
• Volmer T, Effenberger T, Trautner C, et al. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018; 52(4):1800703. doi: 10.1183/13993003.00703-2018.
   PubMed Web of Science ®Google Scholar
• Asthma Canada. Asthma Facts and Statistics 2020 November 2021]. Available from: https://asthma.ca/wp-content/uploads/2020/07/Asthma-101.pdf.
   Google Scholar
• Müllerová H, Cockle SM, Gunsoy NB, et al. Clinical characteristics and burden of illness among adolescent and adult patients with severe asthma by asthma control: the IDEAL study. J Asthma. 2021;58(4):459–470. doi: 10.1080/02770903.2019.1708095.
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Dalal AA, et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract. 2016; 4(1):120–129.e3. doi: 10.1016/j.jaip.2015.08.003.
   PubMed Web of Science ®Google Scholar
• Sadatsafavi M, Khakban A, Tavakoli H, et al. Trends in oral corticosteroids use in severe asthma: a 14-year population-based study. Respir Res. 2021;22(1):103. doi: 10.1186/s12931-021-01696-x.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Canada. Xolair (omalizumab): Product monograph. Montreal (Canada); 2017. Available from: https://pdf.hres.ca/dpd_pm/00070876.PDF
   Google Scholar
• GlaxoSmithKline Inc. Nucala (mepolizumab): Product monograph. Mississauga (Canada); 2020. Available from: https://pdf.hres.ca/dpd_pm/00067402.PDF
   Google Scholar
• Teva Canada Innovation. Cinqair (reslizumab): Product monograph. Montreal (Canada); 2017. Available from: https://pdf.hres.ca/dpd_pm/00038484.PDF
   Google Scholar
• AstraZeneca Canada. Fasenra (benralizumab): Product monograph. Mississauga (Canada); 2020. Available from: https://pdf.hres.ca/dpd_pm/00054955.PDF
   Google Scholar
• Sanofi-aventis Canada. Dupixent (dupilumab): Product monograph. Laval (Canada); 2021. Available from: https://pdf.hres.ca/dpd_pm/00071250.PDF
   Google Scholar
• Reibman J, Tan L, Ambrose C, et al. Clinical and economic burden of severe asthma among US patients treated with biologic therapies. Ann Allergy Asthma Immunol. 2021;127(3):318–325.e2. doi: 10.1016/j.anai.2021.03.015.
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. doi: 10.1016/j.chest.2020.08.2083.
   PubMed Web of Science ®Google Scholar
• Casale T, Molfino NA, Silver J, et al. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities. Ann Allergy Asthma Immunol. 2021;127(3):354–362. e2. doi: 10.1016/j.anai.2021.05.021.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Colice G, Griffiths JM, et al. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020;21(1):1–10. doi: 10.1186/s12931-020-01503-z.
   PubMed Web of Science ®Google Scholar
• Voorham J, Xu X, Price DB, et al. Health care resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74(2):273–283. doi: 10.1111/all.13556.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777–792. doi: 10.1080/14728222.2020.1783242.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946. doi: 10.1056/NEJMoa1704064.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. doi: 10.1186/s12931-020-01505-x.
   PubMed Web of Science ®Google Scholar
• AstraZeneca Canada Inc. Tezspire (tezepelumab): Product monograph. Mississauga (Canada); 2022. Available from: https://pdf.hres.ca/dpd_pm/00066831.PDF
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Recommendation - Tezepelumab (Tezspire). 2022.
   Google Scholar
• Rind DM, McQueen RB, Herron-Smith S, et al. The effectiveness and value of tezepelumab for severe asthma: a summary from the institute for clinical and economic review”s California technology assessment forum. J Manag Care Spec Pharm. 2022;28(5):577–580. doi: 10.18553/jmcp.2022.28.5.577.
   PubMed Web of Science ®Google Scholar
• González-Barcala FJ, Muñoz-Gall X, Mariscal E, et al. Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain. J Med Econ. 2021;24(1):874–882. doi: 10.1080/13696998.2021.1941065.
   PubMed Web of Science ®Google Scholar
• Tohda Y, Matsumoto H, Miyata M, et al. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan. J Asthma. 2021;59(11):1–12.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;84(19):1800–1809. doi: 10.1056/NEJMoa2034975.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Review Dupilumab (Dupixent). 2021.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. CADTH Pharmacoeconomic Report Benralizumab (Fasenra). 2018.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation Reslizumab (Cinqair). 2019.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation Mepolizumab (Nucala). 2016.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada, 4th edition 2017 October 2021]. Available from: https://www.cadth.ca/guidelines-economic-evaluation-health-technologies-canada-4th-edition.
   Google Scholar
• Menzies-Gow A, Steenkamp J, Singh S, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ. 2022;25(1):679–690. doi: 10.1080/13696998.2022.2074195.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: National Institute for Health and Care Excellence (NICE) ; 2014.
   Google Scholar
• Pan-Canadian Pharmaceutical Alliance. Brand Name Drug Negotiations Status. Updated 2022 2022 [February 27, 2022]. Available from: https://www.pcpacanada.ca/negotiations.
   Google Scholar
• Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022;10(7):650–660. doi: 10.1016/S2213-2600(21)00537-3.
   PubMed Web of Science ®Google Scholar
• Observational and Pragmatic Research Institute Pte Ltd. Oral corticosteroid exposure and chronic disease onset (data on file). 2017.
   Google Scholar
• EQ-5D. About EQ-5D-5L [December 2022]. Available from: https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/.
   Google Scholar
• Xie F, Pullenayegum E, Gaebel K, et al. A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care. 2016;54(1):98–105. doi: 10.1097/MLR.0000000000000447.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800–804. doi: 10.1177/0272989X11401031.
   PubMed Web of Science ®Google Scholar
• National Institute of Care and Excellence. Benralizumab for treating severe eosinophilic asthma. Technology appraisal guidance [TA565]. 2019.
   Google Scholar
• Statistics Canada. Table 13-10-0114-01 Life expectancy and other elements of the complete life table, three-year estimates, Canada, all provinces except Prince Edward Island 2021 July 2021]. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310011401.
   Google Scholar
• To T, Simatovic J, Zhu J, et al. Asthma deaths in a large provincial health system. A 10-year population-based study. Ann Am Thorac Soc. 2014;11(8):1210–1217. doi: 10.1513/AnnalsATS.201404-138OC.
   PubMedGoogle Scholar
• Ontario Drug Benefit [Internet. ]. 2021 cited December 2021]. Available from: https://www.formulary.health.gov.on.ca/formulary/.
   Google Scholar
• GlaxoSmithKline Inc. Advair Diskus: Product monograph. Mississauga (Canada); 2020. Available from: https://pdf.hres.ca/dpd_pm/00056976.PDF
   Google Scholar
• Mylan Pharmaceuticals ULC. Wixela Inhub: Product monograph. Etobicoke (Canada); 2020. Available from: https://pdf.hres.ca/dpd_pm/00055254.PDF
   Google Scholar
• AstraZeneca Canada Inc. Symbicort Turbuhaler: Product monograph. Mississauga (Canada); 2021. Available from: https://pdf.hres.ca/dpd_pm/00059997.PDF
   Google Scholar
• Organon Canada Inc. Zenhale: Product monograph. Kirkland (Canada); 2021. Available from: https://pdf.hres.ca/dpd_pm/00060636.PDF
   Google Scholar
• GlaxoSmithKline Inc. Breo Ellipta: Product monograph. Mississauga (Canada); 2019. Available from: https://pdf.hres.ca/dpd_pm/00049111.PDF
   Google Scholar
• AstraZeneca Data on File. Moderate to Severe Asthma Report Specialist Market. 2021.
   Google Scholar
• Government of Ontario. Job Bank - Registered Nurse (R.N.) in Canada February 2022]. Available from: https://www.jobbank.gc.ca/marketreport/wages-occupation/993/ca.
   Google Scholar
• Government of Canada Job Bank. Registered Nurse (R.N.) in Canada 2021 cited 2021 July 2021]. Available from: https://www.jobbank.gc.ca/marketreport/wages-occupation/993/ca.
   Google Scholar
• Ontario Case Costing Initiative. Costing analysis tool updated 2018 cited 2021 December 2021]. Available from: https://hsimi.ca/occp/occpreports/.
   Google Scholar
• Ontario Ministry of Health. Ontario schedule of benefits; physician services under the health insurance act. 2021.
   Google Scholar
• Ontario Ministry of Health. Ontario exceptional access program formulary 2021 cited 2021 September 2021]. Available from: https://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Common Drug Review Pharmacoeconomic Review Report (Xolair). 2015.
   Google Scholar
• Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. doi: 10.1038/ni.3049.
   PubMed Web of Science ®Google Scholar
• Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37–42. doi: 10.1016/j.anai.2015.10.027.
   PubMed Web of Science ®Google Scholar
• van Nooten F, Stern S, Braunstahl G-J, et al. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in The Netherlands. J Med Econ. 2013;16(3):342–348. doi: 10.3111/13696998.2012.756398.
   PubMedGoogle Scholar
• Sullivan PW, Li Q, Bilir SP, et al. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. Curr Med Res Opin. 2020;36(1):23–32. doi: 10.1080/03007995.2019.1660539.
   PubMed Web of Science ®Google Scholar
• Tan LE, Tan WHG, Aziz MIA, et al. Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore. J Asthma. 2022;59(1):189–199. doi: 10.1080/02770903.2020.1837158.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Diette GB, Rand CS, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med. 2006;174(6):633–638. doi: 10.1164/rccm.200601-007OC.
   PubMed Web of Science ®Google Scholar
• Ando K, Fukuda Y, Tanaka A, et al. Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: a systematic review and network meta-analysis. Cells. 2022;11(5):819. doi: 10.3390/cells11050819.
   PubMed Web of Science ®Google Scholar
• Nopsopon T, Lassiter G, Chen M-L, et al. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis. J Allergy Clin Immunol. 2023;151(3):747–755. doi: 10.1016/j.jaci.2022.11.021.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi: 10.1016/S0140-6736(12)60988-X.
   PubMed Web of Science ®Google Scholar
• Tam V, Ko Y, Mittmann N, et al. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol. 2013;20(2):90–106. doi: 10.3747/co.20.1223.
   PubMed Web of Science ®Google Scholar